Academic Journal
Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy
| العنوان: | Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy |
|---|---|
| المؤلفون: | G Furneri, L Santoni, C Marchesi, S Iannazzo, P Cortesi, P Piacentini, A Caputi, LG Mantovani |
| سنة النشر: | 2016 |
| المجموعة: | Istituto Nazionale di Fisica Nucleare (INFN): Open Access Repository |
| الوصف: | INTRODUCTION: Disease Modifying Therapies (DMTs) have significantly improved clinical conditions of Relapsing Remitting Multiple Sclerosis (RRMS) patients. However, several unmet needs are still relevant in RRMS. Recently, a new therapy, delayed-release dimethyl-fumarate (DMF; also known as gastro-resistant DMF), has been approved and reimbursed by the Italian Drug Agency (AIFA) for the treatment of RRMS.OBJECTIVE: To compare the cost-effectiveness of DMF vs. pharmacological alternatives indicated for the first-line treatment of RRMS in Italy.METHODS: The analysis was conducted from the perspective of the Italian National Healthcare Service (NHS) and outcomes and costs were evaluated over a 50-year time horizon (equivalent to a lifetime horizon). Both outcomes and costs were discounted at 3.5%. The Markov model estimates the clinical and economic consequences of treating RRMS patients with the following therapeutic options: DMF, interferon (IFN) beta-1a intramuscular (IM); IFN beta-1a subcutaneous (SC) at two different doses, 22 mcg and 44 mcg; IFN beta-1b SC; glatiramer acetate (GA) SC 20 mg; oral teriflunomide. Clinical efficacy data used in this analysis came from an elaboration of the mixed treatment comparison (MTC) already published. According to the Italian NHS perspective, only the following direct costs were considered: pharmacological treatment acquisition, treatment monitoring, relapse management, direct costs associated with disability, adverse event management. Administration costs were assumed equal to €0, because every treatment included in the economic analysis can be self-administered. One-way and probabilistic sensitivity analyses were developed and cost effectiveness acceptability curves generated.RESULTS: In the base-case analysis, DMF was more efficacious than alternatives, in terms of both survival (19.496 vs. 19.297-19.461 discounted LYs, respectively), and QALYs (6.548 vs. 5.172- 6.212 discounted QALYs, respectively). Per-patient lifetime costs with DMF amounted to € 276,500, ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | url:https://www.openaccessrepository.it/communities/itmirror; https://www.openaccessrepository.it/record/71464 |
| DOI: | 10.7175/fe.v17i2.1251 |
| الاتاحة: | https://www.openaccessrepository.it/record/71464 https://doi.org/10.7175/fe.v17i2.1251 |
| Rights: | info:eu-repo/semantics/openAccess ; https://creativecommons.org/licenses/by-nc/4.0/ |
| رقم الانضمام: | edsbas.D7218E6C |
| قاعدة البيانات: | BASE |
| DOI: | 10.7175/fe.v17i2.1251 |
|---|